Response to a combination of erlotinib and bevacizumab therapy after immune checkpoint inhibitor

被引:2
作者
Okauchi, Shinichiro [1 ]
Miyazaki, Kunihiko [2 ]
Yamada, Hideyasu [3 ]
Satoh, Hiroaki [1 ]
机构
[1] Univ Tsukuba, Mito Med Ctr, Div Resp Med, Tsukuba, Ibaraki, Japan
[2] Ryugasaki Saiseikai Gen Hosp, Div Resp Med, Ryugasaki, Japan
[3] Univ Tsukuba, Hitachinaka Med Ctr, Div Resp Med, Tsukuba, Ibaraki, Japan
关键词
ACQUIRED-RESISTANCE; JO25567;
D O I
10.1111/crj.13153
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
引用
收藏
页码:500 / 501
页数:2
相关论文
共 4 条
[1]   Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results [J].
Kato, Terufumi ;
Seto, Takashi ;
Nishio, Makoto ;
Goto, Koichi ;
Yamamoto, Noboru ;
Okamoto, Isamu ;
Tao, Liang ;
Yu, Wei ;
Khaznadar, Tarik ;
Tajima, Kosei ;
Shibata, Masahiko ;
Seki, Akihiro ;
Yamamoto, Nobuyuki .
DRUG SAFETY, 2018, 41 (02) :229-237
[2]   Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC [J].
Li, Shuai ;
Zhou, Fangyu ;
Ren, Shengxiang ;
Zhou, Caicun .
LUNG CANCER, 2014, 84 (02) :203-205
[3]   New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer [J].
Oxnard, Geoffrey R. ;
Arcila, Maria E. ;
Chmielecki, Juliann ;
Ladanyi, Marc ;
Miller, Vincent A. ;
Pao, William .
CLINICAL CANCER RESEARCH, 2011, 17 (17) :5530-5537
[4]   Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study [J].
Seto, Takashi ;
Kato, Terufumi ;
Nishio, Makoto ;
Goto, Koichi ;
Atagi, Shinji ;
Hosomi, Yukio ;
Yamamoto, Noboru ;
Hida, Toyoaki ;
Maemondo, Makoto ;
Nakagawa, Kazuhiko ;
Nagase, Seisuke ;
Okamoto, Isamu ;
Yamanaka, Takeharu ;
Tajima, Kosei ;
Harada, Ryosuke ;
Fukuoka, Masahiro ;
Yamamoto, Nobuyuki .
LANCET ONCOLOGY, 2014, 15 (11) :1236-1244